Phase II trial of miniDOX (reduced dose docetaxel–oxaliplatin–capecitabine) in “suboptimal” patients with advanced gastric cancer (AGC). TTD 08-02
Titel:
Phase II trial of miniDOX (reduced dose docetaxel–oxaliplatin–capecitabine) in “suboptimal” patients with advanced gastric cancer (AGC). TTD 08-02
Auteur:
Rivera, F. Massutí, B. Salcedo, M. Sastre, J. Martínez Galán, J. Valladares-Ayerbes, M. Serrano, R. Paredes, Mª. L. García de Manzano, J. L. Galán, M. Alsina, M. Yuste Izquierdo, A. L. López, C. Díaz-Rubio, E. Conde, V. Reboredo, M. Cano, Mª. T. Pachón, V. Aranda, E.